The TB:HIV Project
“Co-infection with Mycobacterium tuberculosis among HIV-infected patients in Europe” is a prospective European multi-cohort study.
Tuberculosis (TB) is the most frequent coinfection among HIV-infected patients worldwide. Use of combination antiretroviral therapy (cART) may significantly influence the clinical presentation, management and prognosis for HIV-infected patients coinfected with Mycobacterium tuberculosis, as well as the incidence of this disease. Furthermore, there may be major regional diversities across Europe in these clinical issues related to TB.
There are still, several unresolved issues related to the optimal management of TB in the HIV-infected patient. These include the clinical approach to interactions between HIV and TB therapies, the overlapping toxicity between these treatments, and the role of prophylaxis against TB. The best time to initiate cART and TB therapy in relation to each other, particularly in patients with advanced HIV infection, remains a clinical dilemma because of the concern regarding potential immune reconstitution inflammatory syndrome (IRIS)
The long-term objective of this project is to describe and analyse the aspects mentioned above and potential regional diversities therein. This will ultimately lead to a better understanding of the clinical management of HIV and TB coinfection as well as any regional diversity in Europe and the underlying reasons.
Updated: 15 Nov 2012